fbpx Skip to content


More than 1,000 eye care professionals worldwide have been using the AdaptDx® and AdaptDx Pro® to test for impaired dark adaptation, the earliest biomarker of age-related macular degeneration. Our customers tell the story of how they’re fighting against preventable blindness by identifying AMD at its earliest stages and closely monitoring its progression. 

I strongly believe that if we can catch AMD at a very early stage – and proactively recommend supplements, blue light filters, sunglasses, plus tell them to watch their BMI and cholesterol levels – we can stop or slow this down and help preserve their vision.

Laurie Sorrenson, OD, FAAO Laurie Sorrenson, OD, FAAO

Thanks to the comprehensive AMD Excellence training program from MacuLogix, each staff member - from the front desk and optical, to technicians and billing - understands the important role they play in AMD care.

R. Aaron Werner Aaron Werner, OD

After learning the specifics about pre-clinical macular degeneration and the opportunity I have to identify this devastating disease in my patients much earlier than ever before, it was a no-brainer that all my patients with risk factors or over the age of 50 must have the AdaptDx test done.

RyanPowell Ryan Powell, OD

AdaptDx more than paid for itself within the first few months.

Tammy Tully 2 Tammy Tully, OD

The impact of the AdaptDx on my patient care and practice revenue has been phenomenal!

Pam Lowe Pamela Lowe, OD

The AdaptDx is simple for the patient and takes little staff training to become proficient at administering. Analyzing the data by the doctor only takes seconds and is very simple to interpret. This allows more time to discuss with the patient the results and the plan of action when needed.

EricHammond Eric Hammond, OD

The test is a great benchmark that I use to determine depth of the disease and how soon the patient needs to return for another visit.

Mogyordy Pete Mogyordy, OD

Now that we are using the AdaptDx to help us diagnose AMD earlier and actively manage disease progression, I’m confident we will improve outcomes in both eyes by catching CNV before significant vision loss occurs.

R. Aaron Werner Aaron Werner, OD

I have macular degeneration and I'm glad we caught it early, because now we can do something about it.

Linda Grumbine Linda G., AMD Patient

It would be unimaginable nowadays to diagnose glaucoma without both structural and functional testing. With today’s technology, the same can be said for AMD, as functional testing complements structural findings for the earliest indications of the disease.

Leo Semmes, OD, FAAO Leo Semes, OD, FAAO